Thursday, June 11, 2015

March/April SNPits Summary

In the March/April issue of UF Health Personalized Medicine Program's e-newsletter, SNPits, a recent study in the Lancet supports the benefit of pharmacogenomic testing for warfarin dosing is reviewed.  The authors found that those patients with warfarin-sensitive genotypes were more likely to be over-anticoagulated in the first 90 days.  Additionally, there were more overt bleeding events for patients with warfarin-sensitive genotypes.  Read more.
Post a Comment